| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 01/16/2007 | US7163681 Isolated monoclonal antibody comprising a light and heavy chain variable of given sequence; diagnosing, treating and preventing prostate/colon cancer and renal carcinoma |
| 01/16/2007 | CA2366065C Topical cosmetic composition comprising bifidobacterium and plant extracellular matrix |
| 01/16/2007 | CA2263911C Treatment of autoimmune diseases |
| 01/11/2007 | WO2007006041A2 Imaging and therapeutic method using monocytes |
| 01/11/2007 | WO2007004975A1 Heparin coating of biological tissue |
| 01/11/2007 | WO2007004912A1 Allergen |
| 01/11/2007 | WO2007004832A1 Composition comprising an extract of crinum asiaticum linne having anti-allergic and anti-inflammatory activity |
| 01/11/2007 | WO2007004705A1 Glycolipid derivative and therapeutic agent comprising the same as active ingredient |
| 01/11/2007 | WO2007004613A1 THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE AND TNF-α PRODUCTION INHIBITOR |
| 01/11/2007 | WO2007004543A1 Pharmaceutical composition comprising 2-pyridone derivative as active ingredient |
| 01/11/2007 | WO2007004523A1 Pharmaceutical composition and beverage composition comprising l-arginine |
| 01/11/2007 | WO2007004405A1 Stealth cells |
| 01/11/2007 | WO2007003948A2 Core 2 glcnac-t inhibitors |
| 01/11/2007 | WO2007003904A2 Prophylactic and immunomodulatory compositions and uses |
| 01/11/2007 | WO2006116950A3 A composition, its preparation method and its use |
| 01/11/2007 | US20070010677 Process for production of piperidine derivatives |
| 01/11/2007 | US20070010569 4-Methyl-5-(2-oxo-1,2-dihydroindol-3- ylidenemethyl)-1H-pyrrole-2- carboxylic acid; cancer |
| 01/11/2007 | US20070010530 Inhibiting the proteolytic activity of cathepsin S; 1-[4-(5-Chloro-1H-indol-3-yl)-piperazine-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2-ol; antiarthritic agent; autoimmune disease: lupus, rheumatoid arthritis, and asthma |
| 01/11/2007 | US20070010521 Condensed polycyclic compounds |
| 01/11/2007 | US20070010515 [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof |
| 01/11/2007 | US20070010494 Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator |
| 01/11/2007 | US20070010483 Glucocerebroside treatment of liver disorders |
| 01/11/2007 | US20070010457 Caspase inhibitors and uses thereof |
| 01/11/2007 | US20070009964 competing with natural OX40L for blocking OX40R-mediated cell signaling in the prophylaxis and/or treatment of diseases related to activated T cells |
| 01/11/2007 | US20070009951 Gene expression vaccine |
| 01/11/2007 | US20070009892 Method of preparing epitopes chimeric gene vaccine |
| 01/11/2007 | US20070009528 Antibodies to masp-2 |
| 01/11/2007 | US20070009522 administering to an Rh-negative individual in need of an anti-Rh(D) monoclonal antibody, wherein monoclonal antibody exhibits a Fc gamma RTIII-type ADCC ( antibody-dependent cell-mediated cytotoxicity (ADCC) assays) level greater than 80% relative to a reference polyclonal anti-Rh(D) human antibody |
| 01/11/2007 | US20070009513 Novel method of screening |
| 01/11/2007 | US20070009507 Fibrin citrulline derivatives and their use for diagnosing or treating rheumatoid arthritis |
| 01/11/2007 | US20070009488 Feline granulocyte macrophage colony stimulating factor nucleic acid molecules |
| 01/11/2007 | US20070009487 Minimal promoters and uses thereof |
| 01/11/2007 | DE202006007499U1 Verwendung einer Zusammensetzung, die Plexin-A1-DAP12-Interaktion inhibiert, zur Behandlung von Entzündungs-, Autoimmun- oder Knochenresorptionserkrankungen Use of a composition, the Plexin-A1-DAP12 interaction inhibited for the treatment of inflammatory, autoimmune or bone resorption |
| 01/11/2007 | CA2614102A1 Core 2 glcnac-t inhibitors |
| 01/11/2007 | CA2613350A1 Glycolipid derivative and drug containing the same as active component |
| 01/11/2007 | CA2612621A1 Heparin coating of biological tissue |
| 01/11/2007 | CA2612241A1 Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| 01/11/2007 | CA2612239A1 Il-12/p40 binding proteins |
| 01/10/2007 | EP1741779A2 Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine mediated toxicity |
| 01/10/2007 | EP1741722A2 Polymorphisms in the human P2X7 gene |
| 01/10/2007 | EP1741718A2 Expression of lipoproteins |
| 01/10/2007 | EP1741443A2 Combination meningitidis B/C vaccines |
| 01/10/2007 | EP1741438A1 Pharmaceutical preparation containing bacterial cell wall skeleton component |
| 01/10/2007 | EP1741428A2 Cell adhesion inhibitors |
| 01/10/2007 | EP1740617A1 Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo |
| 01/10/2007 | EP1740579A1 Tricyclic pyrazole kinase inhibitors |
| 01/10/2007 | EP1740192A2 Method for stimulating the immune, inflammatory or neuroprotective response |
| 01/10/2007 | EP1740144A2 Phototherapy systems and methods |
| 01/10/2007 | EP1417227B1 Peptides eefective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/10/2007 | EP1416885B1 Devices for delivery of therapeutic agents with variable release profile |
| 01/10/2007 | EP1414440B1 N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands |
| 01/10/2007 | EP1339745B1 Immunotherapeutic methods and molecules |
| 01/10/2007 | EP1322330B1 Modulation of allergic response |
| 01/10/2007 | EP1305051A4 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer |
| 01/10/2007 | EP1232180B1 Polypeptides derived from vitamin d nuclear receptor, and their uses in particular for screening vitamin d analogues |
| 01/10/2007 | EP1109803B1 Substituted imidazoles having cytokine inhibitory activity |
| 01/10/2007 | EP1087946B1 Aryl alkanoylpyridazines |
| 01/10/2007 | EP1017723B1 Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use |
| 01/10/2007 | EP0794793B1 Composition for prevention and treatment of hiv-1 infection comprising at least two different hiv-1 reverse transcriptase inhibitors |
| 01/10/2007 | CN1894244A Aryl ether substituted imidazoquinolines |
| 01/10/2007 | CN1893975A Medicament comprising inhibitors of long pentraxin ptx3 |
| 01/10/2007 | CN1893970A Beta-amyloid-analogue-cell epitop vaccine |
| 01/10/2007 | CN1893952A Pyrrolo[2,3-D]pyrimidine compounds for treating transplant rejection |
| 01/10/2007 | CN1893937A Use of compositions comprising oleanic acid and ursolic acid for the preparation of a medicament for the treatment of hypersensitivity and hyperreactivity |
| 01/10/2007 | CN1893925A In vivo targeting of dendritic cells |
| 01/10/2007 | CN1891716A No mitogen activity anti CD3 small molecular antibody designing method |
| 01/10/2007 | CN1891714A Ligand for herpes simplex virus entry mediator and methods of use |
| 01/10/2007 | CN1891699A Therapeutic morpholino-substituted compounds |
| 01/10/2007 | CN1891693A Therapeutic morpholino-substituted compounds |
| 01/10/2007 | CN1891267A Chinese medicine for treating atrophic arthritis |
| 01/10/2007 | CN1891212A Oral preparation and its preparing method |
| 01/10/2007 | CN1294253C Bacterial strains, processed plant extract, composition containing thereof, preparation method and application in treatment and industry |
| 01/10/2007 | CN1294142C 17 beta-carbothioate 17 alpha-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| 01/10/2007 | CN1294141C 6 alpha., 9 alpha-difluoro-17.alpha.-[(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent |
| 01/10/2007 | CN1294135C Pyrrolopyrimidines as protein kinase inhitibors |
| 01/10/2007 | CN1294117C Amidino compound and salts thereof useful as nitric oxide synahase inhibitors |
| 01/10/2007 | CN1293880C Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
| 01/10/2007 | CN1293876C New use of 1,3-propylene glycol derivative |
| 01/10/2007 | CN1293875C Cell growth regulating factor S and its preparation process |
| 01/10/2007 | CN1293866C Cell growth regulating factor II and its preparation process |
| 01/10/2007 | CN1293865C Cell growth regulating factor R and its preparation process |
| 01/09/2007 | US7161002 Compounds as antiinflammartory agents, antiproliferation agents and and anticancer agents from cyclodehydration of compounds |
| 01/09/2007 | US7160987 Administering a monoclonal antibodie, that bind specifically to one or more preselected CD45R leukocyte antigens, including CD45RB epitope for prevention or reversal of transplant rejection or therapy of autoimmune diseases |
| 01/09/2007 | US7160903 Sulfonylaminocarboxylic acids |
| 01/09/2007 | US7160900 Tetrahydropyridino or piperidino heterocyclic derivatives |
| 01/09/2007 | US7160891 Therapeutic treatment of autoimmune disease, transplant rejection, rheumatoid arthritis, by administering 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline |
| 01/09/2007 | US7160889 Quinazoline compounds |
| 01/09/2007 | US7160885 Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity |
| 01/09/2007 | US7160883 Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
| 01/09/2007 | US7160874 Phenylalanine derivatives |
| 01/09/2007 | US7160870 Thrombopoietin mimetics |
| 01/09/2007 | US7160863 Fusion protein contains amino acid sequence with 9 to 13 residues of arginine; antagonist of Nuclear Factor Activated T cell (NFAT); short effectiveness and no side effects or antigenicity; signal sequence, immunosuppressants, biodrugs |
| 01/09/2007 | US7160685 Peptides having SEQ ID NO: 2 with immunogenic epitopes activating CD8+ class I major histocompatibility complex restricted cytotoxic T-lymphocytes for patients harboring latent HCMV infection in the absence of active viral replication; using enriched antigen presenting cells; vaccines |
| 01/09/2007 | US7160549 including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter |
| 01/09/2007 | US7160541 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 01/09/2007 | CA2467490C Pharmaceutical compositions of 5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene |
| 01/09/2007 | CA2309790C Bacterial vaccines comprising auxotrophic, attenuated strains of listeria expressing heterologous antigens |
| 01/09/2007 | CA2294033C Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
| 01/09/2007 | CA2263129C Mammalian cell surface antigens; related reagents |
| 01/09/2007 | CA2260145C Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1 |